7 assets in Mucinous Adenocarcinoma

Therapeutic assets addressing Mucinous Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Irinotecan Mucinous Adenocarcinoma	Stony Brook University	P3	BB (66)
Carboplatin Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P3	B (60)
Docetaxel Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P3	B (60)
Ipilimumab Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Mucinous Adenocarcinoma	University Hospital, Akershus	P2	CCC (53)
Oxaliplatin Mucinous Adenocarcinoma	University Hospital, Akershus	P2	CCC (52)
Samuraciclib Mucinous Adenocarcinoma	University Health Network, Toronto	P1/2	CCC (48)